Search Results 1811-1820 of 16957 for monoclonal antibody
Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PDL2, anti- CTLA-4 antibodies, other checkpoint inhibitors. Other protocol ...
Prior treatment with Cluster of differentiation 33 (CD33) antibody Further exclusion criteria apply. Participating Mayo Clinic locations. Study statuses ...
Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8 weeks use of radioimmunotherapy within 6 months; Known seropositive for or ...
Antibody-based demonstration of an mito defect or residual activity of an mito complex 20%–30% in a tissue, 30%–40% in a cell line, or 30%–40% in >2 tissues ...
Has POEMS (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) syndrome or multiple myeloma ...
Virus (HIV) (positive HIV-1/2 antibodies) Prior or second invasive malignancy, except nonmelanoma skin cancer, completely resected cervical carcinoma in ...
quantitative IgM monoclonal protein > 1,000 mg/dL. ANC ≥ 1000/uL; Hgb ≥ 9 g/dl; PLT ≥ 75,000/uL; Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or if ...
Documented allergic reactions or similar to antibody treatments; Concurrent malignancies other than BCC, other than those with negligible risk of metastases ...
Completion of, if applicable, radiotherapy, chemotherapy, antibodies and immunoconjugates including brentuximab vedotin and/or another investigational drug ...
Presence of anti-mitochondrial antibodies (AMA) in serum (≥ 1:40 on immunofluorescence); Liver histological (based on liver biopsy) findings consistent with ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.